RAPT Therapeutics, Inc. (RAPT)

US — Healthcare Sector
Peers: CNTB  TYRA  XLO  MLYS  MOLN  ANTX  PHVS  PEPG  GLUE  DSGN  HOWL  IKNA  STOK  ANEB  PMVP  ELYM  HCWB  RLAY  PLRX  BDTX  ARVN 

Automate Your Wheel Strategy on RAPT

With Tiblio's Option Bot, you can configure your own wheel strategy including RAPT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol RAPT
  • Rev/Share 0.0
  • Book/Share 3.2937
  • PB 0.2848
  • Debt/Equity 0.0216
  • CurrentRatio 21.1104
  • ROIC -0.6779

 

  • MktCap 124100310.0
  • FreeCF/Share -2.0182
  • PFCF -1.1418
  • PE -0.4336
  • Debt/Assets 0.0204
  • DivYield 0
  • ROE -0.8147

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 5
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed RAPT H.C. Wainwright -- Buy -- $6 May 22, 2025
Upgrade RAPT H.C. Wainwright Neutral Buy -- $10 Dec. 26, 2024

News

Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know
RAPT
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive

Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Read More
image for news Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know

About RAPT Therapeutics, Inc. (RAPT)

  • IPO Date 2019-10-31
  • Website https://www.rapt.com
  • Industry Biotechnology
  • CEO Dr. Brian Russell Wong M.D., Ph.D.
  • Employees 67
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.